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Schizophrenia is a severe an enduring psychiatric condition occurring in around 1% of the general 
population. In addition to clinical symptoms, sufferers show neuropsychological deficits. Neuroimaging 
changes including deficits in frontal and temporal lobe structures can be seen in subjects with the condition. 
Of the many aetiological perspectives of Schizophrenia the heritability of the illness and the role of excess 
of the neurotransmitter dopamine are important. Dopamine is degraded by two enzymes COMT and 
MAOA. Thus mutations in the genes controlling the effectiveness of these enzymes may render subjects 
with a hyperdopaminergic state. This thesis will concentrate on two specific Single Nucleotide 
Polymorphisms in the MAOA and COMT genes and their consequences on the clinical, neuropsychological 
and neuroimaging phenotype. The study population for this thesis will be taken from the Edinburgh High 
Risk Study. This is a prospective cohort of individuals at high risk of schizophrenia due to having two or 
more relatives with the condition. It is in this population that the effects of the genes may be studied 
without the contaminating effects of psychotropic medication or other illness factors. 
The results from this thesis show that COMT genotype can be related to structural and functional 
neuroimaging changes. Additionally MAOA genotype appears to have a significant effect on affective 
symptoms and neuropsychological traits. These findings suggest a mechanism for how a 
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Schizophrenia: Historical Perspectives and Aetiology 
 
The historical origins of schizophrenia hinge critically on the phenomenological 
description of both symptoms and course of the illness. Emile Kraepelin (1) proposed the 
fundamental substrate of what is presently understood as Schizophrenia, which he termed 
“Dementia Praecox”. While the clinical portrayal of the condition became more refined, 
its’ genesis remained nebulous. By the time Kraepelin wrote the final (eighth) edition of 
his textbook in 1913, he had concluded that the causes of Dementia Praecox were 
wrapped in “impenetrable darkness”. (2) 
 
Over the past century however, the understanding of the illness has been accelerated due 
to important findings in genetics, neuroimaging and psychopharmacology. However, the 
symptomatic description of the illness remains critical to the diagnosis. Thus far genetic 
and neuroimaging findings have not been sufficient to overtake clinical diagnosis as the 
gold standard. Findings from genetic studies have demonstrated the importance of the 
heritability of the illness and current estimates suggest that approximately 80% of the 
aetiology of schizophrenia is considered to be genetic. (3) Neuroimaging findings have 
shown structural differences between the brains of schizophrenic patients and normal 
controls. Increased ventricular size, decreased hippocampi and temporal lobe structures 
and changes in frontal lobe function have all supported change in structural 
neuroanatomy as a basis for the illness. (4) The finding that the brains of schizophrenia 
 8 
sufferers have decreased brain weight and size has lead towards the theory that 
schizophrenia may be a degenerative condition wherein these findings are a result of the 
illness process. (5) 
 
Along with studies in genetics and neuroimaging, a further line of inquiry has followed 
the serendipitous finding that Dopamine receptor blockade has a therapeutic effect in 
Schizophrenia. Such findings have founded the idea that Schizophrenia (or at least 
Psychosis) is in some way related to excess of the neurotransmitter Dopamine. This 
theory founds the “Dopamine Hypothesis” first described by Carlsson and Lindquivst in 
1965. (6) Further pharmacological work supports Dopamine receptor blockade as a 
treatment measure and critically, dopamine receptor “D2” blockade has been firmly 
established as being the main therapeutic measure. (7). Further studies have shown that 
post mortem brains of Schizophrenic patients have increased Dopamine receptor 
sensitivity (8). Furthermore Amphetamine, a compound which enhances Dopamine 
release, has been shown to cause an acute syndrome, clinically indistinguishable from 
Psychosis. (9) 
 
Significant epidemiological findings in schizophrenia include a higher prevalence in 
those born in the winter (10), a higher rate of obstetric complications (11) and the 
apparent rise in cases experiencing a second trimester gestational insult such as maternal 
influenza (12) amongst those who develop Schizophrenia. As the early development of 
the central nervous system is characterised by neuronal migration, cell proliferation and 
cell death, intrauterine and prenatal complications could have major impact on 
 9 
neurodevelopment. Preterm babies have been shown to develop a higher incidence of 
cognitive and behavioural disorders. (13) A number of early studies have noted mild 
neurological deficits in those who go on to develop Schizophrenia. These deficits have 
included gross neurological measures in infants (14) such as delayed motor milestones of 
development, lower educational test scores in adolescence and solitary play preferences 
in childhood. (15) Such work has supported the “Neurodevelopment Hypothesis of 
Schizophrenia” (16, 17). This suggests that the origins of Schizophrenia may be found 
long before the onset of symptoms which could be related to some early insult to the 
nervous system. 
 
One strategy that has been employed more recently to investigate this is to look at 
individuals at high risk of Schizophrenia due to family history and study their phenotype 
prior to the onset of the illness. (18) This line of enquiry may demonstrate the occurrence 
of clinical, neuropsychological or neuroimaging changes as precursors to the illness. 
 
In summary, the evidence described above is the foundation for five established 
perspectives of Schizophrenia. Firstly, that based on twin and adoption studies and a 
universally similar incidence, Schizophrenia has a strong genetic heritable determinant. 
Secondly, Schizophrenia is an illness which is associated with increased Dopaminergic 
metabolism. Thirdly, Schizophrenia is a brain disorder characterised by macroscopic 
neuroimaging and microscopic neuropathological changes. Fourthly, that neurological 
antecedents leading to cognitive and behavioural change predate the illness, lead to a 
widely held view that schizophrenia has the semblance of a neurodevelopmental disorder. 
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Lastly, these changes persist through the course of the illness and suggest that the illness 
may show the pattern of a neurobiological disorder. 
 
However, a complete understanding of Schizophrenia remains elusive. Of the many 
questions that remain, some of the most important relate to which genes are involved, at 
what stage and how they play a part in the occurrence of symptoms, neurological and 
cognitive deficits and structural and functional brain changes.  
 
Due to the known role of excess Dopamine in Schizophrenia, this thesis will concentrate 
on two genes associated with Dopamine degradation and how mutations in these genes 
may affect the symptoms, neuropsychological indices and neuroimaging findings. These 
will be studied in a population at high risk of Schizophrenia as it is in this population that 
a phenotype, uncontaminated by the chronic effects of the illness or medication, can be 












Schizophrenia: The Clinical Phenotype 
 
The main clinical description of Schizophrenia is given in the International Classification 
of diseases volume 10 (ICD-10) (19) and Diagnostic and Statistical Manual of Mental 
Disorders (DSM IV) (20). These descriptions give an indication of best practice for 
diagnosis. The Schizophreniform disorders are characterized in general by fundamental 
and characteristic distortions of thinking and perception, and affects that are inappropriate 
or blunted. Clear consciousness and intellectual capacity are usually maintained although 
certain cognitive deficits may evolve in the course of time. The course of schizophrenic 
disorders can be either continuous, or episodic with progressive or stable deficit, or there 
















Inclusion Criteria At least one of the following must be present 
1) Thought echo, thought insertion or 
withdrawal or thought broadcasting 
2) Delusions of control, influence or passivity, 
clearly referred to body or limb movements 
or specific thoughts actions or sensations 
3) Hallucinatory voices giving a running 
commentary on the patients behaviour or 
discussing the patient between themselves 
or other types of hallucinatory voices 
coming from some part of the body 
4) Persistent delusions of other kinds that are 
culturally inappropriate and completely 
impossible 
Or at least two of the following : 
1) Persistent hallucinations in any modality 
when occurring every day for at least 1 
month, when accompanied by delusions 
(which may be fleeting or half formed) 
without clear affective content or when 
accompanied by persistent overvalued ideas 
2) Neologisms, breaks or interpolations in the 
train of thought, resulting in incoherence or 
irrelevant speech 
3) Catatonic behaviour such as excitement, 
posturing or waxy flexibility, negativism, 
mutism and stupor 
4) Negative symptoms such as marked apathy, 
paucity of speech and blunting or 
incongruity of affect 
Exclusion Criteria That the patient meets the criteria for manic 
episode or depressive episode the criteria must have 
been met before the mood disturbance developed 
The disorder is not attributable to organic brain 
disease or to alcohol or drug related dependence or 
withdrawal 
Table 1. ICD Criteria for Schizophrenia 
 
As can be seen above, Schizophrenia is composed of positive symptoms (including 
hallucinations and delusions) and negative symptoms. The negative symptoms are 
characterised by social withdrawal and cognitive decline.  
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Neuroanatomical Findings in Schizophrenia 
 
There existed an interest in the Neuropathology of schizophrenia as early as the time of 
Kraepelin. (21) Subsequent use of Pneumoencephalopathy (22) suggested differences 
between the brains of schizophrenics compared to controls though the methodology of 
such studies was limited. There have been many gross Neuroanatomical findings 
following the introduction of Computerised Tomography (CT) and Magnetic Resonance 
Imaging (MRI) as research tools for psychiatric diseases. These include: a slight but 
significant reduction in brain mass, a significant reduction in the anteroposterior length of 
cerebral hemispheres and a decrease in cerebral mass including reduction of the cerebral 
hemispheres, cerebral cortex and central grey matter in patients with Schizophrenia 
compared to controls. (23) 
 
One study (24) noted that the brain weight was reduced by 4.5%, brain length was 
reduced by 1cm (females) and 0.7cm (males) and ventricular size was increased. This 
study also noted that and excess of non-specific “focal pathology” (affecting the caudate 
and putamen) was detected. Lastly an excess of gliosis was noted, most significantly 
affecting the cerebral cortex, white matter and periventricular regions.  
 
In a detailed review (25) of post mortem schizophrenic brains compared to controls,  it 
was demonstrated that the volumes of the right and left hippocampal formation and 
internal pallidum were significantly smaller in the schizophrenia group. The hippocampus 
and pallidum in both hemispheres were equally affected. With the exception of the left 
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caudate, male patients were more affected than females. In addition to this, other research 
(26) found that the parahippocampal gyrus was significantly smaller in the schizophrenic 
group compared to controls. Other major studies have concluded that the Temporal lobe 
volume is reduced in schizophrenia. This finding specifically attributes the reduction to 
loss of grey matter at the level of the amygdala and anterior hippocampus. 
 
There have also been findings regarding the histopathological changes in schizophrenic 
brains. Pyramidal cell disorientation in the hippocampus has been reported by two studies 
(27) (28). A further study found that schizophrenia patients had significantly lower 
pyramidal cell density than normal controls in the left CA4 hippocampal region. (29) 
Cytoarchitectural abnormalities in the entorhinal cortex have also been shown. (30) A 
meta-analysis (31) found that relative to the cerebral volume differences, the regional 
volumes of the subjects with Schizophrenia were 94% in the left and right amygdala, 
94% in the left and 95% in the right hippocampus/amygdala, and 93% in the left and 95% 
in the right parahippocampus. Relative to the global ventricular system differences, the 
largest differences in ventricular subdivisions were in the right and left body of the lateral 
ventricle, where the volumes of schizophrenic subjects were 116% and 116%, 
respectively. (32) 
 
The structural neuroimaging findings exemplify schizophrenia as a brain disease. While 
this might seems an obvious conclusion, an issue remains as to the direction of causality 
between the illness and the brain changes. On one hand, do the changes precede and thus 
lead to the clinical syndrome or, alternatively could some of the changes be attributed to a 
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compensatory reaction. A third possibility is that the brain changes are simply an 
epiphenomenon, unrelated to the central disease process, yet co-existent with cases.  
 
Below is a table of established neuroimaging findings in Schizophrenia. This table also 
shows the findings from the subjects in the Edinburgh High Risk Study as genotype will 



















Replicated finding Evidence EHRS population 
(Lawrie et al. 2001) (41) 
Ventricular enlargement Johnstone 1976 (33), 
Pearlson 1993 (31) 
Non significant reduction 
Reduced Brain volume Elkis 1995 (32)  
Hippocampal Reduction Barta 1990 (34), Shenton 
1992 (35) 
See below 
Prefrontal Cortex Buchanan 1998 (36) Non significant reductions 
Superior Temporal Cortex Barta 1990, (34) Shenton 
1992 (35) 




Anterior Cingulate Cortex Job 2002 (37) Significant reduction 
Reduced Thalamic Volume Andreasen 1994 (38) Both left and right 
thalamus are significantly 
smaller in High risk group 
Table 2: Neuroimaging in Schizophrenia 
 
Structural abnormality of anterior cingulate and medial prefrontal cortex is arguably one 
of the most consistently replicated findings in schizophrenia (39, 40, 41) and has 




Neuropsychological Findings in Schizophrenia 
 
More recent evidence has accumulated showing that schizophrenia is associated with 
significant impairment in cognitive functioning. Specifically, deficits in attention, 
memory, and executive function have been consistently reported in patients with 
schizophrenia. 
 
Many studies have shown that patients with schizophrenia have widespread 
neuropsychological impairments (44) compared to controls along with evidence of 















Construct Recorded test variables Evidence from meta-
analysis 
Mean effect size 
Global Verbal Memory CVLT trails 1-5 




Selective Verbal Memory CVLT, WMS 
RAVLT 
0.90 
Non-verbal Memory ROCFT, WMS, RMT 
faces 
0.74 
Motor FTT 1.30 
Attention WAIS-R digit span 













Spatial ability Benton facial recognition 
WAIS- block design 
 
0.61 
Executive function WCST 0.88 
Language function Word fluency 





Table 3: Neuropsychological Findings in Schizophrenia 
Above is a table of neuropsychological measures comparing normal controls to 
schizophrenia patients. The effect size is measured as an odds ratio. Taken from 

































Premorbid IQ 98.46 105.82 0.771 0.001 
Executive function 
Stroop incongruous condition 
Stroop difference between 
control and incongruous 
Verbal fluency (FAS) 
























































Perceptual motor speed 10.93 12.37 0.44 0.025 
Table 4: Neuropsychological Findings in Schizophrenia in EHRS 
 
Above is a table comparing subjects at high risk of schizophrenia due to family history 
with controls on a number of Neuropsychology measures. Taken from Byrne et al 
2003(47) 
 
In summary, schizophrenia is a condition with an established clinical phenotype. 
Neuroimaging and neuropsychological findings in schizophrenia are significant but not 
highly specific to the condition. For the purposes of the thesis psychological, 
Neuroanatomical and clinical features will be referred to as dimensions of the illness and 





The Dopamine Hypothesis 
 
The Dopamine hypothesis has been the pre-eminent hypothesis for the aetiology of 
schizophrenia and was first proposed by Carlsson and Lindqvist in 1963. (6)  
 
Animal models have been extensively used to assess the dopamine hypothesis. Methods 
include sensitization of animal behavior by Amphetamine, Phencyclidine, or excess 
steroids; removing various genes (COMT, DBH, GPRK6, RGS9, RIIbeta); making brain 
lesions in newborn animals, or delivering animals abnormally by Caesarian section. All 
of these methods induce a marked behavioural super sensitivity to Dopamine and a 
marked rise in the number of dopamine D2 receptors in the high-affinity state for 
dopamine. (48) This work implies that there are multiple genes and neuronal pathways 
that can lead to Psychosis and that all these multiple psychosis pathways converge via the 
high-affinity state of the D2 receptor, the common target for all Antipsychotics.  
 
In addition some of the best evidence for the theory is from the effect of drugs such as 
Amphetamine and Cocaine. Extensive reviews (49) highlight the fact that up to 75% of 
patients with schizophrenia have increased signs and symptoms of their Psychosis upon 
challenge with moderate doses of methylphenidate or amphetamine or other dopamine-




This link between dopamine blockade and antipsychotic action was strengthened by 
evidence that the affinity of antipsychotic drugs for the D2 dopamine receptor family 
seemed to be correlated with the reduction of psychotic symptoms. (49)This correlation 
between the therapeutic doses of antipsychotics and their affinities for the dopamine D2 
receptor was reported by Delay and Deniker (50)  
 
The original hypothesis was based on the understanding that Dopamine only innervated 
sub cortical regions and that these regions were over stimulated by excessive Dopamine 
transmission (51, 52). 
 
It has been suggested that overactivity of dopamine systems in the mesolimbic pathway 
may contribute to the 'positive symptoms' of schizophrenia (such as delusions and 
hallucinations), whereas problems with dopamine function in the mesocortical pathway 
may be responsible for the 'negative symptoms', such as avolition, flat emotional response 
and alogia. (53) 
 
However later work (52), demonstrated additional dopamine cortical projections and an 
opposite and reciprocal regulation of cortical and sub cortical dopamine projections. The 
revised dopamine hypothesis therefore proposed that hyperactive mesolimbic dopamine 
tracts contributed to the positive symptoms of schizophrenia and under active 




Hypoactive cortical Dopaminergic pathways have been subsequently confirmed by 
functional imaging studies. Dopamine D1 receptor binding is reduced in the prefrontal 
cortex but not in the Striatum of drug naïve schizophrenic patients (56) 
 
Hyperactive sub cortical dopaminergic activity has been confirmed by PET studies which 
have demonstrated an amphetamine-induced excessive release of Dopamine in the 
striatum in patients with schizophrenia (57). Over activity of the Striatum has been 
previously associated with the positive symptoms of schizophrenia. Studies of Raclopride 
(a selective dopamine D2 antagonist) suggested no evidence of altered D2 receptor levels 
in the basal ganglia in drug naïve schizophrenics. But studies using N-methyl Spiperone 
did indicate an elevation. An elevated endogenous level dopamine obscures an 
abnormally high concentration of D2 receptors. 
 
It is postulated that this dopamine dysregulation arises from the development of 
“sensitisation”, the process whereby repeated exposure to a drug induces not tolerance 










The Metabolic Pathway of Dopamine 
 
Dopamine, like other catecholamine neurotransmitters, is synthesized from the amino 
acid precursor, tyrosine, which has to be taken up through the blood brain barrier by a 
transporter into the dopaminergic cells (58). The first step in the synthesis of 
catecholamines is the hydroxylation of tyrosine to DOPA, by tyrosine hydroxylase, which 
is also the rate limiting enzyme in the synthetic cascade. 
 
In the cytoplasm of cells, DOPA decarboxylase transforms DOPA to dopamine, which is 
then carried by another active transporter to synaptic vesicles, where the molecules are 
protected from catabolizing enzymes. The synthesis rate of the dopamine is dependent on 
the activity of the tyrosine hydroxylase, an enzyme which is under the control of many 
mechanisms (59). The main short-term regulatory factors are end-product inhibition, 
firing rate of the neuron and autoreceptors located in the nerve-endings. The end-product 
of the dopaminergic neurons, dopamine, decreases the affinity of the enzyme's pteridine 
co-factor for tyrosine hydroxylase, which results in a decrease of enzyme activity. All of 
the above-mentioned mechanisms, as well as many other factors (59), regulate the 






Figure 1: Dopamine Metabolism 
Dopamine synthesis and its major metabolic routes. COMT = catechol-O-
methyltransferase, MAO = monoamine oxidase, 3-MT = 3-methoxytyramine, HVA = 
homovanillic acid, DOPAC = 3,4-dihydroxyphenylacetic acid. 
 
Inside the Dopaminergic cells the cytosolic dopamine is metabolized mainly by two 
successive reactions. First, monoamine oxidase (MAO) transforms dopamine to a 
corresponding aldehyde, which then can serve as a substrate for aldehyde dehydrogenase 
to produce 3,4-dihydroxyphenylacetic acid (DOPAC). DOPAC then diffuses out of the 
cells and can be either conjugated to glucuronides or transformed to homovanillic acid 
(HVA) by catechol-O-methyltransferase (COMT) (60, 61, 62). A portion of MAO is 
located outside of the dopaminergic neurons, i.e. in the glial cells, while COMT is found 
only outside dopaminergic neurons. A fraction of the released dopamine, the size of 
which varies in different brain areas (63) is first O-methylated by COMT to 3-
methoxytyramine (3-MT) and then oxidized by MAO to form HVA (64).  
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Since COMT does not exist inside the dopaminergic neurons (65, 66, 67), all 3-MT found 
in the brain should be derived from dopamine that is released from the nerve endings. 
 
Based on this scheme, it has been suggested that the 3-MT concentration in the brain 
tissue (65, 66, 67) or interstitial fluid (68, 69) would be an indicator of dopamine release. 
Indeed, it has been shown that 3-MT levels in brain are elevated during electrical 





Figure 2: Dopamine in the Synapse 
Metabolism of dopamine in the dopaminergic nerve terminal and synapse. DA = 
dopamine, COMT = catechol-O-methyltransferase, MAO = monoamine oxidase, 3-MT = 




In summary, the dopamine hypothesis provides an aetiological basis for psychotic 
symptoms and consequently schizophrenia but has notable limitations. Importantly for 
this thesis both COMT and MAO play a significant role in dopamine metabolism and 
merit study in the aetiopathology of schizophrenia  
 
 
The Genetic Basis for Schizophrenia 
 
As early as the 19th century, Sir Francis Galton, (70) among other medical innovations, is 
considered to be the first to use twins to study the “relative powers of nature and nurture”. 
He described a pair of identical twin brothers concordant for some kind of psychosis, then 
termed “monomania”, whose symptoms included paranoid delusions, auditory 
hallucinations and mood swings – a putative clinical description of schizophrenia. (70)  
In 1916, working with Kraepelin, Rudin performed the first systematic family studies, 
finding the increased prevalence of the illness amongst relatives. (71) Thus genetic 
factors appeared implicit in elucidating a biological basis for the disorder. The twin study 
method was subsequently developed by Siemens (72) in a more scientific format. In 1928 
Luxenburger conducted the first systematic study of twins. While a genetic influence on 
the illness was established, Luxenburger sought to identify the degree of penetrance of an 
alleged gene given the pattern of inheritance did not conform to simple Mendelian theory. 
(72) Luxenburgers’ results were largely inconclusive due to the small sample size and it 
was not until 1946 when a more robust demonstration of the method was executed by 
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Kallman. (72) In 1967 Eisenberg, noted that “these findings (adoption and twin studies) 
persuade me……not only that there is a genetic component in the transmission of 
schizophrenia but that it is a significant determinant of the occurrence of the disease”. 
(72)  Gottesman 1991 notes that “a renewed appreciation began for twin data” following 
this statement. (73) 
 
Latterly, six major twin studies have been conducted from 1963 to 1987 in Finland, 
Norway, Denmark and the UK. These countries appear to show consistent, conservative 
diagnostic systems hence making their amalgamation valid. These studies combine to 
show that Monozygotic (MZ) twins appear 48% concordant for schizophrenia and 
Dizygotic (DZ) twins are only 17% concordant. The implication being that, when the 
environment is controlled, a higher degree of genetic similarity correlates to a higher 
clinical concordance. 
 
A further arm in assessing the hereditable basis for schizophrenia is the use of adoption 
studies (74). Here, adoptees of schizophrenic parents are observed to have a higher 
likelihood of contracting the disorder, irrespective of the family they were brought up in.  
 
The 1988 the World Health Organisation conducted a worldwide study of the 
epidemiology of Schizophrenia. (75). The findings showed that from as disparate cultures 
and climes as Denmark, India, Japan and Honolulu, the lifetime risk of schizophrenia was 
remarkably similar (0.8-1.4%). The natural conclusion is that, irrespective of 




The studies above demonstrate the imperative implication of genes in schizophrenia. This 
necessitates the question of which genes are involved and how they affect both the 
cellular and clinical phenotype. 
 
Since the advent of studies of candidate genes for schizophrenia, a question arises as to 
the function of these genes in the developmental neuropathology of illness. Some of the 
most promising candidates include COMT (76), NRG-1 (77) and BDNF (78). These 
genes have cellular products which, according to traditional hypotheses, could be 
involved in the pathological process of schizophrenia. However, a gap in knowledge 
exists in how the gene products bear any relation to as diverse manifestations of 
schizophrenia as working memory, schizoid personality traits and structural brain 
changes. The relatively new field of functional genomics in schizophrenia attempts to 
correlate candidate genes with neuroimaging, neuropsychological and clinical findings. 
With regards to schizophrenia there exist three main questions. Firstly, which 
characteristics of the illness are genetically mediated? These would be differentiated from 
prenatal or perinatal factors and environmental factors such as substance misuse and 
stress. Secondly, there arises the question about which genes correlate to which 
phenotypic characteristics and thirdly what the magnitude of the effect is. While we 
appear to be far away for understanding how genes cause the phenotypic characteristic 
directly, the focus in functional genomics has shifted to whether and which. Therefore the 
task lies in elucidating which genes are implicated in which changes in schizophrenia. 
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Different strategies have been employed to find whether genes have an effect on a 
particular trait. Twin and adoption studies have been the primary methods for this. High 
risk studies look at which characteristics precede illness and case control studies look at 
which traits appear disease specific. All of these methods can be used when choosing 
which characteristics should relate to the function of a candidate gene. One possibility is 
that the putative genes influence cortical migration (79). Thus if structural brain 
abnormalities in schizophrenia patients are genetically determined they could be a major 
biological marker for transmission of the schizophrenia genotype (80) 
 
Although the genetic basis remains unclear, the evidence from family, twin and adoption 
studies indicates that the majority of risk is likely to be due to genetic factors. It is clear 
that unaffected family members share many of the neuropsychological (81, 82, 83) and 
imaging abnormalities (84, 85) found in affected individuals, albeit to a lesser degree, 
Further, some of these abnormalities are positively associated with the genetic proximity 
to an affected relative (86, 87, 88, 89). This suggests that the alleles which underlie the 
genetic risk to schizophrenia may primarily exert their effects on intermediate traits such 
as frontal lobe structure or function. Such ‘intermediate phenotypes’ may ultimately be 
more useful in understanding the biology of psychosis than diagnoses based on the 








Twin studies have provided the bedrock of assessing genetically mediated manifestations 
of illness and the magnitude of environmental effects. An important method to study 
genetic impact on schizophrenia phenotype is to look at monozygotic twins, discordant 
for schizophrenia. Follow-up study of the offspring of MZ twins with a diagnosis of 
schizophrenia and their MZ co-twins without schizophrenia demonstrated equal rates of 
schizophrenia; hence, each group of offspring carried equal genetic vulnerability for the 
illness. Indeed it is noted that “studies of differences between members of discordant MZ 
twins have great potential for shedding light on non genetic and epigenetic mechanisms 
that contribute to aetiology” (90). The main variables thus far studied include both 
structural and functional neuroimaging, neuropsychological tests and clinical variables.  
 
Twin Studies, Neuroimaging and Neuropsychology 
 
The inclusion of discussion about twin studies is important in this thesis as they, in 
conjunction with neuroimaging findings identify which traits in the disorder may be 
genetically mediated. 
 
With regard to Neuroimaging, results are varied. One study (91) found that hemispheric 
volumes were smaller in affected monozygotic (MZ) twins rather than unaffected twins. 
Schizophrenic twins, whether from concordant or discordant pairs, had smaller whole 
brain volumes than control twins. (92) The affected twins showed more abnormalities in 
 31 
hippocampal, third and lateral ventricular volumes than concordant twins in the same 
study. Therefore whole brain volume appears under high genetic control and smaller 
whole brain volume is a reflection of the genetic liability to develop schizophrenia. The 
variation in hippocampal and ventricular volumes within discordant monozygotic pairs 
however, demonstrates the importance of environmental factors in causing these volume 
abnormalities in schizophrenia. 
 
In one study (92) 15 sets of monozygotic twins who were discordant for schizophrenia 
were studied At the level of the pes hippocampi, the hippocampus was shown to be 
smaller on the left in 14 of the 15 affected twins, as compared with their normal twins, 
and smaller on the right in 13 affected twins. In the twins with schizophrenia, as 
compared with their normal twins, the lateral ventricles were larger on the left in 14 and 
on the right in 13. The third ventricle also was larger in 13 of the twins with 
schizophrenia. It was concluded that abnormalities of cerebral anatomy (namely, small 
anterior hippocampi and enlarged lateral and third ventricles) are consistent 
neuropathological features of schizophrenia and that their cause is at least in part not 
genetic. 
 
In further studies (94) of hippocampal morphology, Hippocampal measures were used in 
statistical tests specifically designed to identify disease-associated genetic and non 
genetic influences on morphology. Smaller hippocampal volumes were confirmed in 
schizophrenia.. Disease-associated effects were not present between monozygotic 
discordant co-twins. Monozygotic, but not dizygotic, unaffected co-twins exhibited 
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smaller left hippocampi compared to control twins, supporting genetic influences. Results 
suggested that hippocampal volume reduction may be a trait marker for identifying 
individuals possessing a genetic predisposition for schizophrenia. 
 
Other studies (95) of the hippocampus showed that Hippocampal volumes of affected 
twins were smaller than those of their unaffected MZ and DZ co-twins and healthy twins. 
Hippocampal volumes of affected’ non-ill co-twins were smaller than those of healthy 
twins, but those of non-ill MZ and DZ co-twins of schizophrenic patients were similar.. 
The intra class correlation for healthy MZ pairs was larger than that for discordant MZ 
pairs, and the variance component estimate for additive genetic effects was lower in 
discordant twins than in healthy twins. Though hippocampal volume in healthy 
individuals is affected by genetic factors, it relates to greater modulation by 
environmental factors in schizophrenic patients and their relatives.  
 
(96) Furthermore, like their affected twins, however, unaffected monozygotic co-twins of 
the schizophrenia twins exhibited significant callosal displacements. Lateral and third 
ventricle enlargements were related to callosal displacements. This demonstrates that 
genetic rather than disease-specific or shared environmental influences contribute to 
altered callosal morphology in schizophrenia. An upward bowing of the callosum may 
thus provide an easily identifiable neuroanatomic marker to screen individuals possessing 
a biological vulnerability for schizophrenia 
 
A further study (97) found significantly increased caudate volumes in affected twins 
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compared to their unaffected co-twins, but no significant difference in thalamic volume.  
A study (98) looking at grey matter deficits in twins discordant for schizophrenia found 
disease-specific effects were present in a small fraction of the total surface area affected 
by genetic influences, corresponding primarily to middle frontal gyrus (dorsolateral 
prefrontal cortex) but contributed uniquely to gray-matter deficits in prefrontal regions 
involved in eye movements and motor planning and in temporal and parietal areas that 
support multimodal sensory and perceptual integration, auditory perception, and episodic 
memory.  
 
With regards to functional neuroimaging, Prefrontal physiological deficit on WCST was 
studies for MZ twins discordant for schizophrenia. (98) It was noted that the entire 
distribution of rCBF is shifted towards lower values in schizophrenia population. 
It was further noted that with MRI and rCBF measures, the more affected a twin differed 
from the unaffected twin in left hippocampal volume, the more they differed in prefrontal 
physiological activation during WCST. In affected twins, prefrontal activation was 
strongly related to both left and right hippocampal volume. 
 
In summary, with regards to neuroimaging, findings that appear to be largely genetically 
modified include callosal displacements, thalamic volume and brain volume to a lesser 
degree. Factor which appear less genetically modified include right and left hippocampal 





In a study of quantitative analysis of smooth pursuit eye tracking in discordant twins, 
measures for the affected twin were inferior to the unaffected twin and there was an 
increase in gain and amplitudes of saccadic intrusion. (99) This appeared to be associated 
with expression of illness. 
 
When learning and memory was studied in a similar population, the affected group had 
deficits in story recall, pair association with learning, visual recall of designs and effortful 
and volitional retrieval. Mild impairments in episodic memory were also noted.(100) 
The same author also noted trend levels of significance with regards to the WCST 
between these groups. (101) 
 
As an example of clinical data, significantly greater dysmorphological hand skin signs 
among schizophrenic MZ twins when compared with their non schizophrenic co-twins 
suggested an in utero second trimester fetal developmental abnormality for the 
schizophrenic subjects. (102) 
 
Those traits which are only found in the schizophrenic twin (of discordant MZ twins), 
and appear illness related, must be largely non genetic or disease specific in origin. 
However, it would be impossible to state whether these changes predated or were 
subsequent to the onset of illness. Thus twin studies can tell us whether certain traits in 
schizophrenia are largely genetically modified but not whether these are state or trait 
markers. Twin studies show the chance of a trait being genetically mediated. 
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Candidate Genes for Schizophrenia 
 
Schizophrenia research in the past decade has lead to fruitful findings with regards to 
Candidate genes for the illness. At this time no single gene has been shown to specifically 
associate with the condition but several candidates have shown promising associations. 
The basis for this line of enquiry has followed three major trajectories. Firstly, linkage 
studies (103, 104) have demonstrated genomic areas of interest including regions of 
chromosomes 5q, 3p, 11q, 6p, 1q, 22q, 8p, 20q, and 14p, and less significantly regions of 
chromosomes 16q, 18q, 10p, 15q, 6q, and 17q. (136) Further evidence (137) found the 
strongest evidence for susceptibility loci on 8p (P < 2 x 10(-4)), 13q (P < 7 x 10(-5)), and 
22q (P < 9 x 10(-5)) for schizophrenia. Thus the 8p and 22q regions were supported by 
both meta-analyses but eight other regions were supported by only one. There is greater 
consistency of linkage results across studies than has been previously recognized. The 
results here suggest that some or all of these regions contain loci that increase 
susceptibility to schizophrenia in diverse populations. 
 
Secondly Association studies have found candidates with significant association to the 
schizophrenia phenotype although the results appear more equivocal when these 
candidates are studied in ethnically diverse populations. Below is a table containing the 











COMT Shifman et al 
(105) 
22q11 
BDNF Skibinska et al 
(106) 
11p13 
MAOA Norton et al 
(107) 
Xp11.23 
NRG-1 Stefansson et 
al 2002 (108) 
8p21-22 
DISC-1 Zhang et al 
(109) 
1q42 
Dysbyndin Straub et al 
(110) 
6p22.3 
DAOA Ma et al 2005 
(111) 
13q22–34 
DRD3 Jonsson et al 
2003 (112) 
11q21 
GRM3 Chen et al 
2003 (113) 
7q21.1 
RGS4 Chowdari et al 
2002 (114) 
1q22 
Table 5: Candidate Genes 
 
As can be seen above, only COMT and NRG-1 correspond to the areas of interest in the 
linkage studies, yet other candidate genes show association with schizophrenia albeit 
equivocal. 
 
The third trajectory for finding appropriate candidates relates to the relevance of putative 
gene function in the condition. In this regard candidates such as the Dopamine receptor 
DRD3 would be an obvious choice to be investigated due to the known importance of 
dopamine in schizophrenia. COMT and MAO would, by the same token, necessitate 
investigation. Crucially, however, it must be stated that MAOA does not have high levels 
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of association with schizophrenia. Of all the above candidates the obvious choice for 
study in the present study’s population would be COMT as it fulfils the requirements of 
being a good candidate in association studies, it lies within evidenced linkage regions and 
has a naturally relevant role in dopamine metabolism. Notably MAOA has been cited as a 




















Catechol-O-Methyl Transferase (COMT) and Schizophrenia 
 
The mechanism by which inheritance of the COMT val allele increases risk for 
schizophrenia may be related to its impact on prefrontal DA levels and prefrontal 
function. However, DA neurotransmission in PFC has also been shown in experimental 
animals to affect subcortical DA activity, which is implicated in both the psychotic 
symptoms of schizophrenia (115, 116, 117) and the therapeutic response to anti-
dopaminergic drugs (118). DA flux in PFC modulates the activity of excitatory cortical 
neurons that project both directly and indirectly to mesencephalic DA neurons (119, 120, 
121). Recent evidence in the rodent indicates that, whereas prefrontal neurons make 
direct contacts with DA neurons that project back to PFC, prefrontal projections do not 
contact directly DA neurons projecting to the striatum. This has led to speculation that 
prefrontal neurons tonically inhibit striatal DA projections perhaps via GABA 
intermediates in the striatum or in the brainstem (122, 123). Under experimental 
conditions in animals, reduced DA signaling in the PFC leads to increased responsivity of 
subcortically projecting midbrain DA neurons to stimuli such as stress (124, 125, 126). 
The notion that overactive populations of mesencephalic dopamine neurons might be a 
"downstream" effect of an abnormality in prefrontal function has been proposed as an 
explanation for the coexistence of both cortical and subcortical dopaminergic 
abnormalities in schizophrenia (160, 161, 157, 162). Therefore, to the extent that COMT 
genotype affects prefrontal function, it may contribute risk for schizophrenia not only 
because of its biological effects at the level of PFC but also because of indirect 
downstream effects on DA regulation. 
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The COMT Val allele has been shown to increase the risk of schizophrenia in some 
studies (131), particularly in samples of European origin. As discussed above, it has a 
pivotal role in the extracellular degradation of dopamine and there are many strands of 
evidence to link abnormal dopamine metabolism to the aetiology of schizophrenia. 
Firstly, there is evidence of increased dopamine transmission in people with 
schizophrenia, including some patients who were unmediated and not experiencing acute 
episodes (164). Secondly, there is evidence of state-dependent dysregulation during acute 
episodes (165). Thirdly, it is generally accepted that all currently available antipsychotic 
agents are antagonists at dopamine receptors and that the average daily dose is related to 
their affinity for the D2 receptor form (166).  
 
Whilst alleles at several loci appear to raise the likelihood of developing schizophrenia, 
some members of affected families develop affective disorders or other illnesses which 
lie on the ‘schizophrenia’ spectrum (167, 168) and some of the children of these people 
may develop schizophrenia .  
 
The extent to which each allele ‘carrier’ without schizophrenia shares the 
neuropsychological, imaging and other abnormalities of ill relatives is uncertain. 
Furthermore, whilst certain alleles are more common in people with schizophrenia, it is 
unclear whether the neuropsychological and imaging findings that they have are 
explained by their illness or risk states alone, or are better explained by the particular 
alleles that they carry. These issues are largely unaddressed in the literature although 
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there is evidence that the COMT Val158Met polymorphism is related to executive 
function in healthy controls and in the siblings of affected subjects (169, 170). The 
neuropsychological and imaging correlates of specific loci are of considerable importance 
to the study of schizophrenia since they may define relatively homogeneous phenotypes 
that will permit a more pathophysiological approach to the investigation of affected 
subjects and ultimately inform disease management. 
 
This thesis investigates the role of COMT in a sample of subjects from the Edinburgh 
High-Risk Study (EHRS) of individuals at high genetic risk of developing schizophrenia. 
The risk of schizophrenia associated with the Val allele was first estimated. This was 
followed by an investigation of the structural and functional MRI imaging associations of 
each COMT allele. The specific hypotheses were that the COMT Val allele would be 
related to structural and functional impairment of prefrontal cortex (PFC). This is based 
on a prior study examining the relationship of the COMT Val variant to perfusion of PFC 
(171) and on previous studies which found PFC volume to be related to genetic liability 
to schizophrenia (172, 173).  
 
COMT and functional effects 
 
Several lines of evidence suggest that working memory deficits and associated 
abnormalities in prefrontal cortical structure and function are reflective of an inherited 
diathesis to schizophrenia, and thus represent promising candidate phenotypic markers 
for the disorder. Spatial working memory deficits scale in severity with the number of 
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relatives affected with schizophrenia within families (174). This familial pattern has been 
confirmed to have a genetic basis, as performance on an experimental test of spatial 
working memory was observed to decrease with increasing genetic loading for 
schizophrenia among MZ and DZ twins discordant for schizophrenia and control twins 
(175). These results replicated findings from a previous study of the same sample using 
an extensive battery of clinical neuropsychological tests (176). Notably, in the latter 
study, multivariate methods were employed that accounted for the overlap in 
performance variation among the various tests; spatial working memory, divided 
attention, reaction time to visual targets, and intrusions during verbal memory retrieval 
were the only measures that were found to make unique contributions to the prediction of 
genetic loading for schizophrenia. 
 
In parallel with these findings, structural abnormalities in polar and dorsolateral 
prefrontal regions on MRI varied in a dose-dependent fashion with a degree of genetic 
loading for schizophrenia in the same MZ and DZ twin sample (177). It has been 
suggested that a reduction of interneuronal neuropil in the prefrontal region in patients 
with schizophrenia results in impaired working memory functioning due to hypoactive 
dopaminergic (i.e., D1-receptor-mediated) modulation of pyramidal cell activity (178). 
This prediction has been supported by a recent PET investigation which found increased 
D1-receptor binding in the dorsolateral prefrontal cortex of schizophrenic patients 
compared to controls, which also correlated with reduced working memory performance 
in schizophrenia (179). This result was interpreted as suggesting D1 receptor up-
regulation secondary to reduced prefrontal intracellular dopamine. Altered physiological 
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activity in the prefrontal cortex during performance of a working memory task has been 
observed in both patients with schizophrenia and their unaffected siblings (180, 181).  
 
Given that abnormalities of working memory and prefrontal cortical structure and 
function are associated with genetic liability to schizophrenia, it should be possible to 
identify specific genes that underlie these disturbances. Weinberger and colleagues have 
reported evidence of one such genetic influence – the met/val polymorphism of the 
COMT gene (located in chromosome 22), with val alleles promoting more rapid 
breakdown of synaptic dopamine leading to prefrontal hypofunction in patients with 
schizophrenia (169, 170).  
 
Together, these findings strongly implicate genetic factors as playing a role in the 
abnormalities of prefrontal cortex and working memory in schizophrenia. Nevertheless, 
patients with schizophrenia have been found to show even greater disturbances in DLPFC 
function and structure than their non-ill MZ co-twins (169). Thus, while genetic factors 
may cause patients and some of their first-degree relatives to share a certain degree of 
compromise in prefrontal cortical systems, non-genetic disease-related influences cause 
the DLPFC to be further deviant in the patients, and this added measure of deviance in 
prefrontal cortical function may be among the processes associated with overt symptom 
expression among those genetically predisposed. 
 
The medial temporal lobe structures (i.e., hippocampus, amygdala) and adjacent temporal 
cortex are involved in learning and recall of episodic information, auditory perception, 
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emotion (especially the amygdala) and certain aspects of language processing (182). 
Reductions in temporal cortical and hippocampal volumes are present in both patients 
and their healthy biological relatives (183, 184, 185, 186, 187). From a neurocognitive 
perspective, impaired declarative memory processes that depend on the integrity of the 
hippocampus (188) have been reported in both high-risk adolescents (189) and non-
psychotic relatives of schizophrenics (176, 184, 185, 190), suggesting that they derive in 
part from an inherited genotype. Importantly, two studies have shown a significant 
relationship between deficits in verbal declarative memory and smaller hippocampal 
volumes in relatives of schizophrenia patients (184, 185).  
 
At the same time, however, hippocampal volume reductions and long-term memory 
deficits are specifically more pronounced in patients compared with their own healthy 
MZ co-twins (176, 186). Thus, non-genetic, disease-related factors must also be involved. 











Mono Amine Oxidase (MAO) and Schizophrenia 
 
Monoamine oxidase (MAO) is a mitochondrial enzyme involved in the degradation of 
biological amines including serotonin, dopamine and noradrenaline. In the 1970’s platelet 
MAO activity was thought to be a biological marker for vulnerability to schizophrenia 
(193, 194). Chronic schizophrenic patients, but not those in the acute phase were found to 
have lower activity of platelet MAO when compared to controls (195, 196). Subsequently 
antipsychotic medication was shown to be the likely source of this activity. (197) 
 
In humans two isoenzymes exist: Monoamine oxidase A (MAOA) which degrades 
serotonin and noradrenalin preferentially and Monoamine oxidase B (MAOB) which is 
solely responsible for phenylethylamines and benzyl amine (198, 199). In humans both 
enzymes participate in the degradation of dopamine. Both the MAO genes are located on 
chromosome Xp11.23-Xp11.4 (200). This genomic area has been put forward as a region 
of interest in schizophrenia based on some linkage results in genome screeens of sib-pairs 
and multiplex families (201, 202, 203, 204, 205) 
 
In the brain MAOA is expressed at highest levels in catecholaminergic neurons whereas 
MAOB is most expressed in astrocytes and serotinergic neurons (206, 207, 208). The 
regional variations in the relative contributions of the two forms to the oxidation of 
dopamine result in differences in the proportions of MAOA and MAOB in the different 
regions of the brain (209). Low level of MAOA expression in blood cells has limited the 
study of MAOA in neurological and psychiatric disorders. Both twin (210) and 
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segregation analyses (211) have established that platelet and fibroblast MAO activities 
are controlled by genetic factors. Segregation analysis studies have indicated that this 
genetic control involves a single major locus and molecular studies have indicated that 
this locus is the MAO locus itself (212). A mutation associated with a complete 
deficiency of MAOA enzymatic activity and abnormal behaviour with impulsive control 
disorder has been described within the coding sequence of the MAO gene in one family 
(213). Several DNA polymorphisms have been characterised both for MAOA (214, 215) 
and MAOB (216, 217,218, 219, 220). While these polymorphisms did not affect the 
amino acid sequence of the MAOA protein they did influence the enzyme activity level.  
 
Previous studies of allele frequency of MAOA in the population showed the following 
results (221) 
 
Subjects MAOA MAOA MAOB MAOB 
 Allele 1 Allele 2 Allele 1 Allele 2 
Controls (87) 0.70 0.30 0.47 0.53 
Patients (110) 0.65 0.35 0.50 0.50 
Table 6: MAOA alleles 
 
Here no statistically significant difference was observed between patients and controls 
(MAOA, X=0.61, MAOB, X=0.19 p>0.05 for both) 
However trend level of significance did emerge when the clinical subtypes were 
elaborated. This association came closer to significance when the relationship was 
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studied in males alone (due, in part, to the location of the gene being on the X 
chromosome). Since it had been shown previously that the level of MAO activity is 
proportional to the amount of enzyme protein rather than to different catalytic properties 
of molecules (222), it can be hypothesized that the sequence variation is located within 
the non-coding regulatory region of the gene, which controls the amount of enzyme 
 
The MAOA promoter harbours a Variable Number Tandem Repeat (VNTR) which has 
been shown to influence transcription (223, 224). Alleles with the 3.5 repeats and 4 
repeats were found to transcribe the protein more efficiently than the three repeat allele. 
The 4 repeat allele was shown to induce higher MAOA enzyme activity in human male 
skin fibroblasts than the 3 repeat allele (225). The 3.5 and 4 repeat alleles were also 
associated with higher levels of the serotonergic and dopaminergic degradation products 
5-Hyroxyindoleatic Acid (5-HIAA) and homovallinic acid (HVA) in healthy women. 
(226).  
 
With regard to Monoamine metabolism in MAOA and MAOB deficient mice, gene 
knockout techniques have been a useful tool in understanding the functions of these 
enzymes in vivo. In brains of MAOA knockout mice 5HT levels were only increased two 
fold partly due to the development of MAOB. Noradrenaline levels were increased up to 
two fold and importantly Dopamine levels were found to have increased (230). Dopamine 
levels were not found to have increased in MAOB knockout mice. 
 
MAOA genotype has been associated with other psychiatric conditions. One of the most 
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interesting findings relating to the function of MAOA relates to conduct disorder in a 
study of eight males from a Dutch family (213). Here a single nucleotide polymorphism 
associated with conduct disorder.  
 
MAOA mutations may underlie the susceptibility to alcoholism because MAOA alleles 
have been associated with alcoholism among European populations (233) 
 
One study (234) showed increased salivary MAOA and MAOB is correlated with stress. 
MAOA knockout mice showed increase response to stress in the force swim test (230) 
which would be consistent with the increased levels of Dopamine and Noradrenaline in 
this same population. 
 
Several lines of enquiry have linked 5HT systems with aggressive behaviour (235, 236). 
MAOA knockout mice have elevated brain levels of 5HT and a distinct behavioural 
syndrome including enhanced aggression is manifested by adult males. Similarly elevated 
levels of 5HT may be important in the enhanced emotional learning that the adult 
knockout mice exhibit (237). It is possible that aggression related to MAOA deficiency 
may related to structural changes in the somatosensory cortex (238). MAO A deficiency 
may render mice more susceptible to the effects of environmental substances, drugs or 
biogenic amines (such as dopamine). 
 
More recently MAOA genotype has been found to associate with bipolar disorder (239). 




Monoamine Oxidase A Functional Effects 
 
Some studies have demonstrated the phenotype effects of variants in MAOA genotype. 
One study looked at the effects of MAOA genotype on brain structure and function. (240) 
A common variable number of tandem repeats (VNTR) polymorphism of the MAOA 
gene has been described that strongly impacts transcriptional efficiency: enzyme 
expression is relatively high for carriers of 3.5 or 4 repeats (MAOA-H) and lower for 
carriers of 2, 3, or 5 repeats (MAOA-L) (202). 
 
Analysis of brain structure revealed that allelic variation in MAOA was associated with 
noticeable regionally specific changes in grey matter volume. When compared with 
MAOA-H subjects, MAOA-L individuals showed a significant reduction in volume that 
encompassed virtually the entire cingulate gyrus and bilateral amygdalae, and a 
maximum in anterior cingulate cortex. Additionally, significant reductions in insula and 
hypothalamus were found. Relative to the volume in MAOA-H subjects, reductions 
averaged around 8% in MAOA-L subjects.  Furthermore, a sex-specific (males only) 
increase of approximately 14% in bilateral lateral Orbito Frontal Cortex (OFC) volume in 
MAOA-L men, relative to MAOA-H men was seen. The OFC was the only brain region 
where an interaction effect was found. 
 
In this study fMRI analysis of perceptual matching of angry and fearful faces showed 
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significant activation of amygdala and task-related deactivation of limbic and paralimbic 
regions implicated in emotion processing, a pattern seen previously (203, 204). MAOA-L 
individuals showed significantly increased activity in left amygdala and decreased 
response of subgenual (BA 25) and supragenual (BA 32) ventral cingulate cortex, left 
lateral OFC, and left insular cortex, relative to MAOA-H subjects. It was postulated that 
it is unlikely that the fMRI effects were related to smaller volume in these small 
structures because both increased and decreased reactivity was seen in these various 
limbic regions that showed reduced structural volume in MAOA-L individuals. 
 
MAOA genotype was also studied in relation to emotional memory, i.e., the encoding and 
retrieval of aversively, compared with neutrally, valenced information. A pronounced 
effect was found of genotype and sex in left amygdala and hippocampal formation; men, 
but not women, carrying the low-expression MAOA genotype showed increased 
reactivity during retrieval of negatively valenced emotional material. This effect was 
present for aversive, but not neutral, material and only during retrieval.  
This study also probed the neural correlates of cognitive inhibitory control using a no-go 
“flanker task.” In men only, MAOA genotype had a pronounced effect on activation 
during response inhibition in dorsal anterior cingulate: MAOA-L hemizygotes showed 
deficient activation. This finding is compatible with a previous observation in a small 
group of male subjects (205). Women had no significant effect of genotype, resulting in a 
significant sex-by-genotype interaction at this locus. Again, this functional change was 
located within the cingulate region of maximal structural change related to genotype. 
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Monoamine oxidase A has several areas of interest with regard to variable expression. 
Gene fusion and transfection experiments have suggested that a VNTR located in the 
MAOA promoter affects the transcriptional activity in the transfected cells (223, 224). 
The two main areas of interest include a VNTR at MAO at intron 1 and a VNTR in the 
MAO promoter. Furthermore a SNP8 is located in a region of four exons containing five 
polymorphisms that had been identified at the MAOA locus. Since the polymorphisms 
were in complete linkage disequilibrium only one was selected for the present studies. 
The choice of polymorphism ultimately was that at exon 8 (rs6265) as there is an easy 
















The Edinburgh High Risk Study 
 
High risk studies offer a useful adjunct to understanding functional genomics. High risk 
studies are prospective studies of individuals in whom the risk for schizophrenia is 
enhanced. These studies concentrate on neuropathological and clinical variables that pre 
date the onset of illness. Five main studies have been conducted to date: the Copenhagen 
Project (202), the Helsinki High Risk Study (203), the Israeli High Risk Study (204), 
New York High Risk Project (205) and the Edinburgh High Risk Study (EHRS) (206).  
The difficulty with such studies has been the long interval between identification of cases 
and the clinical manifestations of the illness. The Edinburgh high risk study recruited 
subjects at a much late age thus shortening the follow up period.  
 
The main findings of these studies are in the domains of structural and functional 
neuroimaging, neuropsychological and clinical data. 
 
 The data for the EHRS has been collected serially starting even years prior to the onset 
of illness thus enabling a time axis to be considered in relation to the illness. This allows 
study of which traits are predictive of illness and whether the neurological deficits can be 
seen long before onset or appear in close proximity to illness. This allows investigation of 
the “early lesion” verses “late lesion” debate with regards to neurodevelopmental 
hypothesis of schizophrenia. Additionally, the populations of these studies include 
individuals who, while at high risk of the disorder, remain clinically well. Should this 
population reveal a spectrum of deficits, these individuals could be deemed as belonging 
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to both an intermediate phenotype and genotype. These populations also strengthen the 
assessment of State verses Trait characteristics. 
 
In the Israeli high risk study, current and lifetime psychopathology was assessed in 50 
Israeli children of parents with schizophrenia and re-evaluated at the age of 31. The 
findings support the concept that both familial and environmental factors operate in the 
expression of psychopathology. 
 
The results suggest that attention skills of the adult children of a parent with 
schizophrenia fall between those of schizophrenia patients and controls, and that 
measures of sustained attention and the ability to focus and execute provide the best 
discrimination among groups. Low scores on a digit cancellation test at age 11, but not at 
age 17, predicted which of the children at genetic risk became unwell (24) 
 
In the New York high risk project offspring of schizophrenia mothers were tested at 7-12 
years and further assessed in mid adulthood. Findings include childhood deficits in verbal 
memory, gross motor skills and attention in those who went on to develop schizophrenia. 
It was also noted that substance abuse had a significant interaction with the clinical 
outcome groups. In subjects without substance abuse, those with schizophrenia-related 
psychoses had exhibited significantly more behavioural problems as children than had 
adult offspring with affective or anxiety disorder or with substance abuse only or no 
disorder. The confounding effects of substance abuse should be statistically controlled in 




The Edinburgh high risk study has remarked on several premorbid findings including 
higher levels of psychopathology and aberrant neuropsychological performance. 
Neuroimaging findings include smaller right and left hippocampal volumes, larger right 
and left lenticular nuclei, smaller left and right thalami and smaller third ventricles. 














Two family-based association studies have provided evidence for a role of COMT in 
schizophrenia (209, 210, 211), but it has been unclear how either protein variation would 
increase risk for schizophrenia (212, 213).  
 
One approach used by Egan and colleagues (214) that may improve power to find genes 
for complex disorders is to target biological traits found in ill subjects and their 
unaffected relatives, so-called intermediate phenotypes, rather than clinical diagnosis 
(215, 216). Such traits may be more directly related to the biological effects of 
susceptibility genes. As described, abnormal function of the prefrontal cortex, an 
important aspect of schizophrenia, also may represent an intermediate phenotype related 
to genetic risk for schizophrenia (217, 218). Stable deficits in cognitive functions 
referable to the dorsolateral prefrontal cortex and cortical physiological abnormalities 
during performance of such tasks have been consistently reported in studies of 
schizophrenia (219, 220). Other evidence indicates that healthy siblings of patients, 
including monozygotic co-twins, show similar cognitive and physiological abnormalities 
(211, 221, 222). The subjects from the EHRS would be suitable candidates to test this 
hypothesis. 
 
Electrophysiological studies in primates (223, 224) and rodents (225), and neuroimaging 
studies in humans (226, 227), have shown that dopamine plays an important role in 
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modulating the activity of prefrontal circuitry during performance of working memory 
tasks. Although there are many proteins involved in the biological actions of dopamine, 
COMT, because it metabolizes released dopamine, may be an important factor during 
such prefrontally mediated tasks. Despite COMT's widespread distribution in 
nondopaminergic neurons and glia, pharmacological studies have shown that catabolic 
flux of synaptic dopamine through the COMT pathway is characteristic of the prefrontal 
cortex in contrast to the striatum (227). Studies of COMT knockout mice, similarly, have 
demonstrated that dopamine levels are increased only in prefrontal cortex (228) and, 
remarkably, that memory performance is enhanced. These findings strongly support the 
notion that variation in COMT activity may have neurobiological effects specific to the 
prefrontal cortex.  
 
As discussed, genetically determined variations in COMT activity might affect prefrontal 
cortical activity, especially during executive and working memory tasks. The primary 
hypothesis for this thesis that the high-activity Val allele, because it leads to increased 
dopamine catabolism, would be associated with relatively compromised prefrontal 
function, and, by virtue of this effect, would increase risk for symptoms of schizophrenia 
and neuropsychological deficits.  
 
It has been previously shown  using the Wisconsin Card Sorting Test (WCST) that 
deficits in WCST performance are enduring and core features of schizophrenia and 
predict long term-disability, independent of other cognitive deficits (225); healthy 
siblings of patients with schizophrenia also perform abnormally on it (226, 227). 
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Functional neuroimaging studies have found that the WCST activates the dorsolateral 
prefrontal cortex (228) and that dopamimetic drugs improve performance on this task in 
patients with schizophrenia and enhance the signal to noise of the prefrontal 
physiological response (229, 230). It has been shown that COMT genotype would affect 
WCST performance and that Val/Val individuals would have the poorest performance. In 
this thesis this will be measured using the Hayling Sentence Completion Test. 
 
In one study, to assay prefrontal physiology, functional MRI (fMRI) was used while 
subjects performed the N-back task. This task has been shown to activate dorsolateral 
prefrontal cortex as well as a distributed cortical working memory network (231). FMRI 
results have been described in unaffected siblings, suggesting that inefficient prefrontal 
information processing is related to genetic risk for schizophrenia.  
 
In contrast, the efficiency of the N-back fMRI response in dorsolateral prefrontal cortex 
is enhanced by the dopamimetic drug, amphetamine, in healthy individuals whose 
performance remains stable (232). Thus, deviations of prefrontal physiology can be 
appreciated with this in vivo fMRI assessment even if there is compensation at the level 
of performance accuracy, and changes in cortical dopaminergic function impact on 
physiological efficiency during this task.  
 
It was hypothesized, therefore, that COMT genotype would affect the efficiency of the 
prefrontal fMRI response during this neuropsychological task and would predict an allele 
dosage relationship with activation, with Val/Val individuals being least efficient. 
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With regards to MAOA genotype, when compared with low/high enzymatic activity 
genotype subjects, low activity genotype subjects individuals showed a significant 
reduction in volume that encompassed virtually the entire cingulate gyrus and bilateral 
amygdalae with a maximum reduction in anterior cingulate cortex. (179) It is 
hypothesized that this finding could be replicated in the high risk population. Low 
activity genotype subjects are likely to show increased levels of dopamine thus increasing 
the efficiency of neuropsychological performance in these brain areas. Just as with 
COMT Val Val genotype it is hypothesized that MAOA “TT” subjects will show 
different neuropsychological performance on Hayling Sentence Completion in areas such 
as the cingulate cortex. 
 
Just as COMT genotype was hypothesized to possible relate to development of 
schizophrenia and psychotic symptoms, it is hypothesized that MAOA genotype may 













The main advantages of high risk studies are that various abnormalities can be studied 
that do not reflect the consequences of illness nor medication. The critical brain and 
clinical changes that occur prior to the onset of illness can be studied. Given the evidence 
that schizophrenia may be neurodevelopment in origin it is essential to uncover what 
happens in the brain prior to symptom development.  
The disadvantage with high risk studies is the resources required to find a large enough 
population who will go on to develop schizophrenia. This population will require to be 
followed for the longest period of time to study all precursors to illness. Ideally this 
population would be studied from birth but the chances of not losing a large number of 
individuals by the time they reach the risk period for illness is very high. 
In the Edinburgh high risk study participants were studied from the age of 15. These 
individuals were selected on the basis of their family history. Each participant had atleast 
2 close relatives with schizophrenia. From previous work it could be estimated that these 









Details of the recruitment process have been described in previous papers (251, 252). 
Briefly, individuals with schizophrenia, with a family history of schizophrenia and with 
adolescent relatives, were identified from psychiatric hospital case records in several 
regions of Scotland. Case-note diagnoses of schizophrenia were verified with the 
Operational Criteria Checklist (210). We then approached their unaffected relatives, and 
from them, recruited high-risk subjects aged 16-25 who agreed to participate. A control 
group of healthy individuals without any family history of schizophrenia was recruited 
from the same regions and communities as the high-risk participants. These people were 
of similar age to the high-risk group and their numbers were comparable to the number of 
people expected to develop psychosis.  
 
Members of the high risk and control groups were given a detailed clinical, 
neuropsychological and brain imaging assessment at baseline. The clinical assessment 
included the Present State Examination (PSE, 9th edition), a structured psychiatric 
interview schedule which has been widely used in studies of schizophrenia (211). All 
these assessments were repeated after approximately 2 years in consenting participants 
who had enrolled in the first 2 years of the study. Further clinical, imaging and 
neuropsychological assessments were conducted at further 2-yearly intervals up until 
2004. These included many of the assessments performed earlier, including structural 
MRI, and a functional MRI scan of the brain using the Hayling sentence completion test 
(HSCT). High risk subjects who did not develop schizophrenia were further subdivided 
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into those with or without psychotic symptoms at any assessment (referred to as HR with 
symptoms and HR without symptoms respectively). 
 
 
Figure 3: Study Population Analysis 
 
 




1st Follow up 
2nd Follow up 
10 years 
30 controls & 100 HRs provide sMRI scan 
34 controls & 157 HRs provide cognitive data 
20 controls and 66 HRs provide sMRI scan 
30 controls & 118 HRs provide cognitive data 
21 controls & 69 HRs provide fMRI-Hayling 
scan 
22 controls and 78 HRs provide cognitive data 
0 controls and 21 HRs develop schizophrenia 
15 controls and 79 HRs provide genetic data 
 61 
All subjects, as documented, underwent standardized battery of neuropsychological 
testing including measures of Premorbid intellectual function (National Adult Reading 
Test NART), Full scale IQ (FSIQ), Current intellectual function, Total Verbal Recall, 
Verbal Fluency, Executive Function as measured by the Stroop Test, Word processing,  
Rey Auditory Verbal Learning Test, Rivermead Behavioural Learning Test 
Verbal Recall and the Hayling Sentence Completion Test. MAOA genotype was related 
to mean scores on each of the neuropsychological variables using Independent T-tests. 
Only subjects with Val Val homozygote and Met Met homozygote were compared from 





Genomic DNA was isolated from whole blood and the COMT and MAOA genotype of 
each subject then determined. The COMT gene has a common functional polymorphism 
resulting in a Met to Val substitution in the translated protein (212). The COMT Val 
allele has been shown to raise the likelihood of developing schizophrenia compared to the 
Met form. The target sequence for the Val158Met SNP was submitted to the Assay By 
Design Service for ABI SNP Genotyping Assays. Assays from the service consist of a 
mix of unlabelled primers and TaqMan MGB probes. 
 
Genotyping was performed at the Genetics Core of the Wellcome Trust Clinical Research 
Facility, Edinburgh (www.wtcrf.ed.ac.uk) in 384 well-plates, using the TaqMan 
polymerase chain reaction-based method. Allelic discrimination using this chemistry is 
based on the design of two TaqMan probes, specific for the wild type allele and the 
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mutant allele. Each of the two probes is labelled with a different fluorescent tag (FAM 
and VIC), and each is designed with the gene mutation affecting the middle part of the 
probe sequence. The binding efficiency of the wild type TaqMan probe to the mutant 
allele and vice versa is low due to the mismatch within the TaqMan probe and the target 
sequence; therefore, mismatched binding is highly reduced. The final volume PCR 
reaction was 5μl using 20ng of genomic DNA, 2.5μl of TaqMan Master Mix and 0.125μl 
of 40x Assay by design Genotyping Assay Mix. The cycling parameters are as follows: 
95° for 10 minutes, followed by forty cycles of denaturation at 92° for 15 seconds and 
annealing/extension at 60° for 1 minute. PCR plates were then read on ABI PRISM 
7900HT instrument with SDS v2.1 software.  
 
The relationship of each allele to the risk of schizophrenia was determined by comparing 
the genotype frequencies across controls, and high risk subjects who had or had not 
developed schizophrenia at the study’s 10-year conclusion (213). The significance of any 
difference was determined using a χ2 test. The relative risk of developing schizophrenia 
in high risk subjects with a Val-Val or Val-Met genotype was also calculated.  
 
MAOA 941T > G PCR and RFLP Assay  
Twenty-four ng genomic DNA was amplified with 1.4 pmol each primer: forward, 5  
GAC CTT GAC TGC CAA GAT 3  and reverse, 5  CTT CTT CTT CCA GAA GGC C 
3 , 1X Qiagen buffer, 1.5 mM magnesium chloride, 100 M each dNTP, 1 unit Qiagen 
taq polymerase, in a final volume of 12 L, for 1 cycle of 94°C 3 min, 35 cycles of 94°C 
30 sec, 55°C 30 sec, and 1 cycle 72°C 5 min. To the PCR product, 1 unit of the restriction 
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enzyme Fnu 4HI, 1.5 L 10X NEB2 buffer and 1.3 L water were added to give a final 
volume of 15 L. The PCR product was digested for 4 hr at 37°C to give fragment sizes 
of 135 bp (uncut allele 1) and 65 bp (cut allele 2). Digested PCR product was 
electrophoresed on 2% metaphor agarose: 1% agarose. 
 
Neuroimaging: Structural 
The methods applied to the acquisition, pre-processing and analysis of images are 
detailed in previous papers from this study (214, 215). Each participant underwent MRI 
scanning on a 1T Siemens (Erlangen, Germany) Magnetom scanner. The scan, for the 
volumetric analysis, was a three-dimensional magnetisation prepared rapid-acquisition 
gradient echo sequence consisting of an 180 degrees inversion pulse followed by a fast 
low-angle shot collection (flip angle 12O, TR=10 ms, TE=4 ms, TI=200 ms, relaxation 
delay time 500 ms, field of view 250 mm) giving 128 contiguous 1·88 mm thick slices in 
the coronal plane orthogonal to the Talairach plane. We corrected for any inhomogeneity 
in the head coil.  
 
Voxel-Based Morphometry was performed using the SPM99 toolbox (Wellcome 
Department of Imaging Neuroscience, London). A study-specific template and a priori 
probability maps for grey matter, white matter and cerebral spinal fluid were constructed. 
Using these study specific templates all of the images in the control and high-risk group 
were spatially normalised and segmented, eliminating large-scale differences between the 
subjects, using a 12 parameter affine transformation. All of the resulting GMD segments 
were then smoothed at 12mm full width at half maximum (FWHM) before being entered 
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into our statistical analysis (214).   
 
Average structural images were compared between groups (defined by genotype) on a 
voxel by voxel basis using SPM99. Cluster results are reported for contrast images 
thresholded at T=3, after adjustment for the underling smoothness as described in 
Moorhead et al (2005) (216). The effect of COMT Val allele dose was estimated using a 
2-tailed linear contrast (1 0 -1;-1 0 1) where the alleles are given in ascending order of 
risk (MM MV VV, where M=Met allele and V=Val allele) with correction for multiple 
comparisons as implemented in SPM99 (225, 226). Individuals homozygous for the Val 
or Met allele were also compared to the other groups combined. Subject status (HR with 
no symptoms, HR with symptoms, HR who had progressed to schizophrenia), age, sex 
and number of grey matter voxels (nvox) were included as covariates.  Where a positive 
association was found, the parameter estimates were inspected graphically to check that 
their estimates were ranked in order of increasing or decreasing magnitude. The effect of 
MAOA genotype was measured with a 2-tailed linear contrast (1 0 -1;-1 0 1) in which the 
GG genotype was compared to GT with correction for multiple comparisons.   The 
analysis was corrected for multiple hypotheses testing in the imaging data.  
  
Neuroimaging: Functional MRI 
Functional imaging was carried out approximately 4 years later than the structural scans 
at the Brain Imaging Research Centre for Scotland (Edinburgh, UK) on a GE 1.5 T Signa 
scanner (GE Medical, Milwaukee, WI, USA) equipped with 23mT/m Echospeed 
gradients having a rise time of 200µs. Subjects were imaged with axial gradient-echo 
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planar images (TR/TE=4000/40ms; matrix 64x128; FOV 220x440mm) acquired 
continually during the experimental paradigm. Thirty-eight contiguous 5mm slices were 
acquired within each TR period. Each EPI acquisition was run for 204 volumes, of which 
the first four volumes were discarded. Visual stimuli were presented using a screen (IFIS; 
MRI Devices, Waukesha, WI, USA) placed in the bore of the magnet; corrective lenses 
were used where necessary.  
 
The participants in the study performed the verbal initiation section of the Hayling 
sentence completion test (HSCT, 218) in the scanner. Subjects were shown sentences 
with the last word missing and were asked to silently think of an appropriate word to 
complete the sentence (i.e. without speaking the word), and press a button when they had 
done so, giving a reaction time measure. The task was adapted for fMRI to have four 
levels of difficulty, according to the range of suitable completion words suggested by the 
sentence context (see Whalley et al. 1999 (220) for further details). Sentences were 
presented in blocks of fixed difficulty; each block lasted 40 s and included eight 
sentences. Sentences were presented for a period of 3s followed by a fixation cross for 2s. 
Subjects were instructed to respond at any time by button press until the next sentence 
appeared. The rest condition consisted of viewing a screen of white circles on a black 
background for 40s. The order of the blocks was pseudo-random, and each block was 
repeated four times (different sentences were used for each sentence block). This design 
allowed both a standard subtraction (sentence completion versus rest) and parametric 
analysis (examining areas of increasing activation with reducing constraint/increasing 
task difficulty). Immediately after scanning, subjects were given the same sequence of 
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sentences on paper and requested to complete each sentence with the word they first 
thought of in the scanner. Scores for word appropriateness and reaction time were 
determined for each constraint level.  
 
Scan analysis was performed using SPM99 (Wellcome Department of Cognitive 
Neurology and collaborators, Institute of Neurology, London, UK), and was performed 
blind to the group status of the individual. For each subject, EPI volumes were realigned 
to the first volume in the series using rigid body transformations. The images were then 
normalized to the SPM99 EPI template using a linear affine transformation followed by 
non-linear deformations, and resampled using sinc interpolation to cubic voxels of size 
8mm3. Normalized images were spatially smoothed with a 6mm FWHM kernel to 
minimize residual inter-subject differences, and in order to meet assumptions for 
statistical analysis.  
 
At the individual subject level the data were modelled with five conditions (the four 
difficulty levels and the rest condition), each modelled by a boxcar convolved with a 
synthetic hamodynamic response function. The estimates of the subject’s movement 
during the scan were also entered as ‘covariates of no interest’. Before fitting the model, 
the subject’s data were filtered in the time domain using both a low-pass (4s) and a high-
pass (400s) filter. Contrasts were constructed to examine all four sentence completion 
conditions versus rest, and areas of increasing activation with increasing task difficulty 
(the parametric contrast).  
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For each contrast of interest (sentence completion versus rest, and parametric effects) one 
contrast image per subject was entered into a second level random effects analysis to 
examine areas of activation within each of the three groups, and differences in activation 
between the groups. As the groups were matched on demographic variables, and there 
were no significant differences in movement parameters, we did not include these factors 
as potential confounds in the model.  
 
Statistical maps were thresholded at a level of p=0.01 uncorrected and regions were 
considered significant at P<0.05 cluster level corrected for multiple comparisons, unless 
otherwise stated. All P-values quoted in the text are at the corrected cluster level. Co-
ordinates are given using the Montreal Neurological Institute (MNI) convention. The 
effect of COMT Val allele dose was estimated using a 2-tailed linear contrast (1 0 -1;-1 0 
1) where the alleles are given in ascending order of risk (MM MV VV).  Subject status 
(HR with symptoms, HR without psychotic symptoms, control) was included as the only 
covariate since age, sex and handedness had been shown in a previous analysis to exert 
no statistically significant effect on the results (220).  The small numbers of genotyped 
HR subjects progressing to schizophrenia with fMRI data (n=3) unfortunately precluded 
them from any meaningful statistical analysis. Where a positive association was found, 
the parameter estimates were inspected graphically to check that their estimates were 
ranked in order of increasing or decreasing magnitude.  
 
Finally, for each significant result reported in respect of the fMRI paradigm, we tested for 
subject group (HR with symptoms, HR without symptoms, control) by COMT status 
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interactions to check whether any effect of COMT was generalisable to all HR subjects, 














Groups at Baseline 
Below is data relating to COMT and MAOA genotype groups at baseline. 
1. COMT analysis Groups at baseline 
 HR (no symptoms) HR (with symptoms) HR (schizophrenia) 
 MM MV VV MM MV VV MM MV VV 
Subjects 
(n) 
12 17 6 
13 14 5 
1 3 7 
Families 
(n) 
11 15 6 13 11 4 1 3 6 
Age 





















3/12 10/17 3/6 5/13 5/14 0/5 1/1 1/3 3/3 
SES† 
n,n 
2,10 8,9 3,3 3,10 3,11 1,4 0,1 1,2 2,5 
Height†† 







































sMRI 12 17 6 13 12 5 1 2 7 
fMRI 7 15 4 12 14 5 - - - 
MM: Met-Met, MV: Met-Val, VV: Val-Val, HR: high risk subjects. SES†: paternal socio-economic status (non-manual, 
manual), Height††: height in cm, NART*: predicted full-scale IQ from National Adult Reading Test. s/fMRI refers to 
the number of subjects providing s or fMRI data in each group. The number of genotyped subjects with schizophrenia 
providing a useable fMRI scan was insufficient to allow meaningful statistical analysis. The numbers for these groups 










2. MAOA analysis groups at baseline 
 HR (no symptoms) HR (with symptoms) HR (schizophrenia) 








45 6 6 2 9 0 
Age 
(SD) x    22.7 (3.1) 
21.6 
(2.9) 






27/50 6/7 2/7 0/2 4/10 0/0 
SES† 
n,n 
2,10 8,9 3,10 3,11 0,1 1,2 
Height†† 


























sMRI 45 7 5 0 4  
fMRI 43 6 5 2 - - 
GG: Met-Met, GT: Met-Val, , HR: high risk subjects. SES†: paternal socio-economic status (non-manual, manual), 
Height††: height in cm, NART*: predicted full-scale IQ from National Adult Reading Test. s/fMRI refers to the number 
of subjects providing s or fMRI data in each group. The number of genotyped subjects with schizophrenia providing a 
useable fMRI scan was insufficient to allow meaningful statistical analysis. The numbers for these groups are omitted 













Seventy nine high risk subjects and 15 control subjects provided blood for genetic 
analysis collected over a 6 month period in 2004. Whilst there was no evidence that the 
COMT nor MAOA genotype were associated with being at high-risk of schizophrenia 
(
2
2 df =0.42, p=0.78) or with the presence of psychotic symptoms (
2
2 df =0.07, p=0.87), 
there was evidence that the COMT Val allele was associated with an increased risk of 
schizophrenia within high risk subjects (Fisher’s exact test, p=0.01). Within the high risk 
group alone, the VV compared to the MM genotype had an estimated crude relative risk 
(RR) of 8.2 (95%CI 1.2 to 57.3). The estimated crude RR of the VM compared to MM 
genotype was somewhat smaller (RR=2.5; 95%CI 0.3 to 21.2) suggestive of a dose-













Clinical Variables Results 
 
It can be seen here that there are no significant differences with regard to clinical 
dimensions of the schizophrenia between COMT Val Val and Met Met genotype. The 
variations in Clinical symptom scores between genotypes are calculated using 
Independent T-tests.  
 















.67 1.25 .146 
Tension 
  
1.83 1.70 .842 
Depression 
  
.58 1.05 .242 
Manic 
  












.00 .05 .278 





2. MAOA genotype GT Heterozygote (n=65) verses GG homozygote (n=8) 
It can be noted that there are several significant differences with regards to MAOA 
genotype between GT heterozygote and GG homozygote. Most notably affective 
symptoms such as Mania, over activity, Situational Anxiety and Incoherence are 
significantly different with regards to genotype. Here Independent T-tests were used to 


















































.01 .00 .462 
  





1. MAOA genotype GT Heterozygote verses GG homozygote 
 
Here, the only significant finding with regards to neuropsychological data is the deficit in 
executive function as shown by the Stroop Test and Speed of comprehension. This 
pattern is consistent with frontal lobe deficit seen in schizophrenia and noted to be 
associated with dopaminergic levels. 
 
Table 11 Neuropsychological Variables by MAOA genotype. Each variable is has 
















National Adult Reading 
Test 
  
99.75 99.88 .921 
  
Full scale IQ 
  
99.24 94.63 .612 
  
Total Verbal Recall 
  




           16.33 15.75 .430 
  












Stroop Test 32 
  
















Ravlvi Rey Auditory Verbal 
Learning Test 
  
11.52 9.88 .859 
  








Behavioural Learning Test 
Learning and memory 
  
21.71 20.38 .053 
  
Storyim Rivermead 
Behavioural Learning Test 







Behavioural Learning Test 
Learning and memory  
  
8.223 7.875 .823 
  












Ravlrec Rey Auditory Verbal 
Learning Test  
 
  
6.06 5.88 .913 
  
Hayling Sentence 








Completion errors B 
 
  











2. Neuropsychology Results for COMT genotype.  
 
Table 12: Neuropsychological Variables by COMT genotype. Each variable is has 
specific scoring system.  Met Met (n=23) compared with Val Val (n=19). Significant 





p value (2 










National Adult Reading 
Test 
  
99.13 98.47 .784 
Full scale IQ 
  
96.75 95.37 .685 
. 
Total Verbal Recall 
  
38.48 37.42 .787 
List animals 
  
14.43 15.05 .637 
Stroop Test 3 
  
24.223 28.126 .339 
Stroop Test 31 
  
13.836 14.922 .512 
Stroop Test 32 
  
11.177 12.278 .476 
Speed of 
comprehension 
66.22 60.21 .348 
. 
Ravli Rey Auditory Verbal 
Learning Test 
  
6.91 6.26 .285 
Ravlvi Rey Auditory Verbal 
Learning Test 
  
11.00 10.63 .691 
Rey Rey Auditory Verbal 
Learning Test 
  
53.39 50.42 .299 
Rbmtstan Rivermead 
Behavioural Learning Test 
Learning and memory 
  
21.96 21.11 .216 
Storyim Rivermead 
Behavioural Learning Test 
Learning and memory  
  
8.217 8.458 .804 
Storydel Rivermead 7.435 7.605 .853 
 77 
Behavioural Learning Test 
Learning and memory  
  
Verbal recall total 1 
  
35.86 33.16 .031 
. 
Verbal recall total 2 
  
33.14 30.68 .115 
Ravlrec Rey Auditory Verbal 
Learning Test  
 
  
6.00 5.95 .915 
Hayling Sentence 
Completion errors A 
  
1.29 2.17 .205 
Hayling Sentence 
Completion errors B 
 
  
2.88 3.00 .864 
 
















Key to Neuropsychology Results 
National Adult Reading Test NART 
Premorbid intellectual function 
(FSIQ) Full scale IQ 
 Current intellectual function 
Total Verbal Recall 
 (verbal IQ) Temporal Lobe Function 
Animals 
 (Verbal Fluency) Executive Function 
stroop3, stroop31, stroop32 
(Executive Function) Prefrontal Cortex/Cingulate 
Speedcr 
(word processing) Temporal Lobe Function 
  
Rey, Ravli, Ravlvi ravldelr ravlrec 
Rey Auditory Verbal Learning Test  
Learning and memory, Fronto-Temporal Function 
Rbmtstan, storydel, storyim 
Rivermead Behavioural Learning Test 
Learning and memory (hippocampal function) 
Vrtotal1, vrtotal2 
Verbal Recall Total 
Fronto-parietal Function 
Errsan/errsbn 
Hayling Sentence Completion Test Errors 













Structural Differences at baseline 
Analysis was performed on 74 HR subjects with both genetic and baseline sMRI data. 
Reductions in grey matter density contingent upon the Val genotype were found in right 
(peak coordinates=8, 36, 24, T=4.10, p=0.04, cluster size=2969 voxels) and left (peak 
coordinates=-13, 16, 28, T=4.30, p=0.04, cluster size=5537 voxels) anterior cingulate 
cortex using a linear contrast for trend.  The plot of parameter estimates at the voxel of 
peak difference suggests that the relationship is dose-dependent with increasing levels of 
the Val allele being associated with decreasing density of anterior cingulate cortex. 
Comparing the Val homozygotes to subjects with at least one Met allele revealed a 
similar region of anterior cingulate reduction (BA 32) in those homozygous for the Val 
allele (Peak Coordinates 21, 40, 4, T=4.49, p<0.01, cluster size=4183). Plotting the 
parameter estimates at the voxel of peak difference confirmed that the difference was not 
dose-related. No significant differences were found between Met homozygotes and those 











Analysis was performed on the 57 HR subjects with both genetic and baseline fMRI data. 
This excluded 3 subjects with genetic data who subsequently became unwell. No 
significant differences in reaction time or word appropriateness scores were found 
between the COMT and MAOA groups for any of the 4 levels of sentence difficulty. In 
addition, there were no significant differences in average or maximum head motion along 
or around the x, y or z axes (6 measurements) during the fMRI scanning sequence.  
 
On subtraction analysis (sentence completion versus rest), the COMT Val allele was not 
associated with any significant differences in activation using the linear contrast. 
Similarly, by comparing individuals homozygous for Val or Met with the other two 
groups combined, no differences in activation were found. Contrasting the parametric 
images between COMT genotypes revealed differing patterns of prefrontal activation 
with increasing sentence completion difficulty. Using the linear test for trend (VV>MM) 
demonstrated a significantly greater activation in anterior cingulate cortex (figure 2: peak 
coordinates -10, 52, -2, T=5.62, p<0.001, cluster size=1414 voxels) and posterior 
cingulate cortex (figure Y: peak coordinates -6, -68, 18, T=4.05, p=0.003, cluster 
size=946 voxels). The plot of parameter estimates for each peak within the cluster 
revealed a trend for greater activation in the rank order VV>VM>MM.  Comparing 
individuals homozygous for Val with the other two groups combined revealed a region of 
increased activation in anterior cingulate cortex with the same voxel maxima as stated 
above (peak coordinates -10, 52, -2, T=5.07, p<0.001, cluster size=1468 voxels) and 
additional region of increased activation in BA 45 ventrolateral prefrontal cortex (peak 
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voxels 60, 18, 4, T=3.96, p=0.015, cluster size=721 voxels). Comparing Met-Met 
homozygotes to those with at least 1 Val allele demonstrated no additional regions of 
difference, although increases in both anterior (peak coordinates -10, 52, -2, T=5.62, 
p<0.001, cluster size=1441 voxels) and posterior (peak coordinates 4, -48, 28, T=4.81, 
p<0.001, cluster size=1536 voxels) cingulate activation in those with at least 1 Val allele 
compared to the MM group were found. 
 
The parameter values were extracted at the voxel of maximum difference for each 
significant result (for both the structural and functional imaging results). These values 
were then imported into SAS (version 9.1, SAS Institute, Cary, NC) and the effects of 
group status (HR with symptoms, HR with without symptoms) by COMT group 
interactions investigated by analysis of variance. No significant group*COMT interaction 
was found for the anterior cingulate, posterior cingulate or ventrolateral prefrontal cortex 
results. However, the main effect of COMT remained significant after the addition of the 













Table 13: Brain areas showing increased activation on fMRI during Hayling Sentence 









GT > G N/A   n/s 
Active versus 
rest: 
GT < G Left fusiform/parahippocampal 
gyrus, BA36/35 
5 -24 -40 -18 0.013 
Active versus 
rest: 
GT < G Left superior frontal gyrus, 
BA8 
4.48 -10 28 58 0.016 
Active versus 
rest: 
GT < G Left insula 4.22 -28 12 5 0.017 
Active versus 
rest: 
GT< G Left fusiform/inferior temporal 
gyrus, BA37 
5 -24 -40 -18 0.064 
Parametric: GT > G Right inferior temporal gyrus, 
BA20 
4.95 53 -30 -17 0.002 








Figure 3: Brain Map of functional Magnetic Resonance Imaging during Hayling 
Sentence Completion Task comparing GT genotype with GG genotype for the MAOA 
G941T SNP. (a) Active v rest, (b) Parametric (p=0.001 uncorrected, KE=100, KE=200 




























Figure 4: Structural Magnetic Resonance Imaging in Met Met genotype compared with 
Val Val genotype of the COMT Val158Met SNP: Figure shows regions of significant 
grey matter density reduction associated with Val allele compared to Met using linear 
contrast (-1 0 1). 
 







Figure 5: Parameter estimates are plotted beneath to show intermediate status of 
heterozygous group for Met Met (MM), Met Val (MV) and Val Val (VV) 
 
Anterior Cingulate Cluster 
 





Figure 6: Functional Magnetic Resonance Imaging during Hayling Sentence Completion 
Test showing increased activation in the Anterior and Posterior Cingulate cortex in Val 
Val genotype compared with Met Met genotype of the COMT Val158Met SNP: 
 
















Figure 7: Parameter estimates to show intermediate status of heterozygous group of 
activation on fMRI; Met Met (MM), Met Val (MV), Val Val (VV) 
 
Anterior Cingulate Cortex 
 
                        
 
Posterior Cingulate Cortex 
 
Figure 8: Brain areas showing increased activation of Val Val genotype compared to Met 
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Met genotype on fMRI for an increasing level of sentence completion difficulty during 
the Hayling Sentance completion test (p<0.01). Blue crosshairs are placed in voxel of 




Figure 9: Areas of Increased Activation on fMRI of brain regions by COMT genotype in 
Met Met (MM), Met Val (MV) or Val Val (VV) Parameter estimates are plotted beneath 







This study demonstrates effects of COMT and MAOA genotype on clinical, 




It has been generally acknowledged that to study the effects of candidate genes, large 
investigations have been necessary to produce significant clinical findings. Candidate 
genes in schizophrenia have, as a rule, small effect sizes and thus large populations have 
been used. However, this study population, although small by genetic studies standards, 
has yielded statistically significant results. The extensive characterisation of this sample 
demonstrates many dimensions of the illness including the neuropsychological and 
neuroimaging components of the illness. Furthermore, most genetic studies only 
discriminate between a gross dichotomous phenotype of disordered verses non-
disordered individuals. Here, the in depth study of different symptom variables 
demonstrates how genes may affect some symptoms but not others.  The Edinburgh High 
Risk Study has the advantage of data from individuals before the onset of illness, thus 
being able to measure traits uncontaminated by the effect of medication or disease 
process. In addition to this, it is possible that subjects with familial schizophrenia may be 




One of the limitations of the present study is the small sample size. It is indeed possible 
that with more subjects some of the results may have become significant. Of the original 
157 individuals who entered into the study only 79 were successfully genotyped. Those 
who were genotyped may have been clinically well relative to those who were not as it is 
likely that subjects who were lost to follow up showed a greater clinical deterioration. 
However, 11 of the sample did meet criteria for schizophreniform disorder and only 21 of 
the high risk sample did. It must be noted that this was not a study of gene effect on 
diagnosis so the sample are still a valid cohort in which to study the effect of these genes. 
Of the 79 individuals who were genotyped only 59 had available scans performed. While 
this would be an acceptable number for a neuroimaging study one can question how valid 
this number would be for a study relevant to genetics. 
 
Ultimately, in spite of the sample size, this was a well characterised cohort which was 
assessed blindly and prospectively. Standardised, well validated neuropsychological and 
neuroimaging tools were used to assess this population. 
 
It can be argued that confounding factors such as haplotype from other candidate genes 
may have played a role in the findings but due to the size of the sample this could not be 
adequately controlled for. We cannot address this argument within this investigation.  
 
With regards to the choice of candidates, there can be little question that COMT was an 
obvious gene to study given its role in Velo-Cardio-Facial Syndrome, its linkage findings 
at 22q11 and its well evidenced association. It is perhaps not surprising that this gene 
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yielded the most significant results. Many other studies have failed to find an association 
between COMT and schizophrenia. However, it must be stated that all candidates appear 
to show heterogeneity with respect to ethnic group. Furthermore, this study looked at 
familial schizophrenia and it has been suggested that association may be stronger in such 
samples. 
 
The choice of MAOA as a candidate can certainly be questioned given the fact that it has 
shown very little association with schizophrenia. Additionally it has not been shown to be 
situated in the linkage areas found in the meta-analyses (129, 130). The MAOA knockout 
mice do not show a phenotype that relates to traditional animals models of psychosis. 
MAOA does relate to other disorders as has been described above such as bipolar illness 
and conduct disorder. Its lack of association with schizophrenia cannot in itself be a 
reason for it not be relevant for study in this population however as the well characterised 
sample could (and did) yield significant results. Its known association with affective 
disorder and impulsive traits make it worth studying this gene in a population where these 
dimensions of phenotype are studied. Following the lack of association with 
schizophrenia MAOA has not been used in functional genomic imaging studies in the 
way that COMT and NRG-1 have. Thus this is the first study to relate MAOA genotype 
with Neuroimaging and Neuropsychology in a population at high risk for schizophrenia. 
 
The fact remains however that, as discussed above, the dopamine hypothesis remains as a 
principal theory in the aetiology of schizophrenia. As COMT has been shown to affect 
dopamine levels it would seem only logical to study MAO which does metabolise 
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dopamine as well. (It can be noted that Dopamine receptor and Transporter gene 
polymorphisms would, by the same token, be equally justified lines of enquiry.) The 
initial premise in this study was not that MAO genotype would be shown to be an 
independent risk factor in aetiology but that in combination with COMT genotype it 
could yield measurable effects through the extra burden of excessive dopamine. 
A further valid question regarding the study of MAO was both the choice of enzyme and 
the choice of mutation. Both MAOA and MAOB are known to metabolise dopamine but 
MAOA was chosen. The main reason for this was due to its brain distribution and the fact 
that mouse MAOA knockout mice showed more phenotypic variation than MAOB 
knockouts. Furthermore, MAOA has been continually cited as relevant to other 
psychiatric conditions compared to MAOB which has not.  
 
There have been 4 noted gene mutations in the MAOA. These include two VNTRs in the 
MAOA promoter region and two SNPs in exon 8 (rs6362) and exon 14. Again none of 
these have specifically been shown to associate with schizophrenia. The choice of the 
SNP at exon 8 was for one simple reason. The VNTR polymorphisms exhibit up to 5 
different haplotypes. Given the size of this sample group, to divide a sample of 79 into 5 
would be extremely unlikely to produce group sizes that would be likely to show 
significant results. Therefore rs6362 was chosen as it has a simple dichotomous genotype 
that could easily divide a cohort into two reasonable size groups. It must be noted that it 
would indeed be worthwhile to study the other SNP and VNTRs of MAOA and also the 






With regards to allele frequency COMT yielded a higher proportion of Val Val genotype 
amongst the high risk sample. This study found evidence that the COMT Val allele raises 
the risk of developing schizophrenia in subjects from families where there is more than 
one affected member. This supports an increasing body of literature implicating this locus 
and is plausibly linked to the aetiology of schizophrenia through the action of COMT on 
extra-cellular dopamine (223) Studies have generally failed to find an association 
between COMT and risk of schizophrenia (224).  However, in a population at increased 
risk of schizophrenia for presumed genetic reasons, we have shown that the COMT Val 
allele is associated with an increased risk of developing schizophrenia. 
 
Studies have generally found little association between MAOA and schizophrenia and 
this study adds to this literature that independently MAOA is not an obvious 
susceptibility gene. However, MAOA does produce significant effects with regards to 
other measured symptoms in this cohort such as depressive symptoms, manic symptoms 
incoherence and over activity. This evidence is consistent with the association between 
MAOA genotype and Bipolar Disorder. Notably there was no association with 
hallucinations or delusions. Situational anxiety was found to be relevant at trend level of 
significance. This finding would be consistent with the evidence that MAOA is primarily 
linked to affective symptoms. It is likely that these symptoms are mediated by the failure 
of MAOA to metabolize serotonin or noradrenalin. When COMT and MAOA genotype 
are combined there is an interesting finding that situational anxiety becomes a significant 
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result. (Here carriers of low functioning COMT and MAOA enzymes have significantly 
higher situational anxiety than carriers of the high functioning enzymes).  
 
Neuropsychology Findings 
With regards to the Neuropsychology results there are also interesting findings that relate 
to genotype. Working Memory (WM) has been consistently demonstrated as being 
deficient in schizophrenic patients compared to controls and WM has also been related to 
COMT genotype suggesting that WM is an endophenotype for COMT. This has not been 
demonstrated in this study population. With regards to MAOA there are several 
significant findings. The finding that MAOA GG genotype scores significantly less on 
Stroop Tests may relate to the finding that some aspect of frontal lobe dysfunction. 
Verbal recall was found to be different at a trend level of significance. 
 
These findings are the first evidence of the MAOA endophenotype and may give some 





The COMT Val allele was also associated with reduced grey matter density in anterior 
cingulate and with increasing perfusion of the same region during tasks of increasing 
difficulty. The finding of increasing prefrontal activation for an equivalent level of task 
performance is consistent with impairment of anterior cingulate cortex and with the 
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consequent need for greater perfusion given an equivalent level of task difficulty and 
behavioural response. The COMT Val allele was also associated with an increased 
perfusion of posterior cingulate cortex and ventrolateral prefrontal cortex (BA45) during 
sentences of increasing difficulty, although the latter result was only found in individuals 
homozygous for the Val allele when compared to the remaining groups combined. 
 
Structural abnormality of anterior cingulate and medial prefrontal cortex is arguably one 
of the most consistently replicated findings in schizophrenia (225, 226, 227) and has 
previously been linked to increasing genetic liability, albeit to unidentified loci (228, 
173). The functional correlates of this region mirror the structural abnormality, although 
are in opposite directions and are suggestive of a compensatory mechanism. Medial 
prefrontal cortex is innervated by a diversity of neurones from different brain regions, 
including dopaminergic neurones from the striatum to which it also sends efferent 
connections. These neurones are part of the fronto-striatal pathway and are the structural 
substrate of the dopamine hypothesis of schizophrenia. Increased dopamine receptor 
availability in the striatum has been shown to be related to genetic liability to 
schizophrenia in unaffected subjects (227). It is therefore possible that the finding of 
reduced medial prefrontal grey matter and impaired function are related to striatal 
dysfunction. These Val associated structural and functional changes in medial prefrontal 
cortex have not been found in larger studies of COMT in people with schizophrenia 
(229). This suggest that the structural and functional differences are likely to relate to the 




The COMT Val allele has been linked to impaired perfusion of DLPFC in previous 
studies (228). Although the results of the present study did not replicate this finding 
exactly, subjects with the Val allele activated more ventrolateral prefrontal cortex for an 
equivalent level of task performance and difficulty. This area is adjacent, to that reported 
by Egan and colleagues, and given the spatial resolution of fMRI, may be an overlapping 
region of cortex. In contrast, the association between the COMT-Val allele and increasing 
posterior cingulate activation for increasing level of sentence difficulty is novel, so far as 
any of the authors are aware. This region, in combination with the adjacent precuneus, is 
associated with episodic memory retrieval in healthy human subjects (229, 230), a 
function impaired in the relatives of schizophrenic subjects (258). Abnormalities of 
dopamine metabolism in posterior cingulate have previously been reported in medication-
free schizophrenic subjects (229). Our finding suggests that dopamine-related 
dysfunction in this region may be related to COMT status and be applicable to the wider 
group of subjects at increased familial risk.  
 
With regard to MAOA findings, the significant finding concerning increased left superior 
frontal gyrus is consistent with the neuro-cognitive deficits and clinical data found from 
the genotype. The left fusiform area is connected with verbal recognition which again 
relates to the neuropsychological deficits. Thus far no other studies have validated this 
finding. As the frontal and temporal lobes are highly implicated in schizophrenia this 






The EHRS is one of the largest prospective imaging investigations in psychiatry to date. 
However, there are practical limitations in any study from a single geographical region. 
In order to increase sample size, whilst maintaining the quality of recorded information, 
multicentre investigation will need to become routine. Secondly, since the imaging 
associations of the COMT or MAOA genotype may not be specific to schizophrenia, it 
would be helpful to further refine the behavioural associations of this allele; either by 
examining the associations quantitatively, or by examining the allelic associations in 
other psychiatric disorders.   
 
The main limitations of this study relate to the cohort size. An automatic area of future 
work would be to relate COMT and MAOA genotype in a large population to 
neuroimaging and neuropsychological findings. Other COMT variants should be 
identified, genotyped and studied and importantly the other MAOA SNPs and VNTRs 
would need to be studied. MAOB would also be of great interest. A further line of 
enquiry as mentioned above would be the studying of other genetic mutations of proteins 




In conclusion, this study demonstrates the effect of COMT and MAOA genotype in a 
population at high risk of schizophrenia. Because the sample has been extensively 
characterized the genotype effect can be seen in clinical, neuropsychological and 
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neuroimaging dimensions of the illness. The strength of this study lies in the prospective 
cohort design and the amount of data relating to each subject. COMT can be seen to be 
more obviously involved in the pathogenesis of Schizophrenia but MAOA can only be 
seen to relate to certain dimensions of the illness. Both genes importantly can be studied 
as to their functional effects, irrespective of their place in the pathology of schizophrenia. 
The MAOA data is the first of its kind and may, hopefully lead to a more extensive study 
of this gene in psychiatric illness. Furthermore this study emphasizes the need to 
extensively characterize phenotypes to see a genotype related effect. 
 
The combination of high risk studies with genetics is relatively new in the study of 
schizophrenia. Much work has already been done in the area of functional genomics but 
in these studies it is important to realise that measured brain or psychological changes 
may relate to secondary effects of the illness or indeed medication. High risk studies 
control for this potential confounder by taking subjects prior to the onset of symptoms. 
MAOA has been implicated in a wide variety of disorders but high risk studies only exist 
in schizophrenia. Hence work looking at conduct disorder/antisocial personality disorder 
and anxiety conditions (and indeed Parkinsons disease) will be confounded by many 
factors. 
 
Both genes have been implicated in affective disorders and the results from these studies 
both enhance what has already been known and concentrate on the endophenotypic 
underpinnings of these disorders. It is interesting to find that MAO and COMT in 
combination have effects on anxiety. This finding has already been noted relating MAOA 
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and COMT to neuroticism in the population. (232) Although we report on a 
schizophrenic population these results are still valid due to the extensive measures used 
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